Abstract

The aim of this study was to investigate the use of botulinum toxin type A (BoNT-A) injections and their efficacy on gross motor function for lower limb spasticity in children with spastic cerebral palsy (CP). This retrospective study included 919 injection occasions from 591 children with CP who received a lower limb BoNT-A injection between 2006 and 2016. The Gross Motor Function Measure (GMFM-88), the Modified Ashworth Scale, and the Modified Tardieu Scale were administered before and after injections. Injections were predominantly administered to children under the age of 6 years. The most common muscle injection site was the calf muscle for dynamic foot deformity. The second most commonly injected muscle was the hip adductor among 2–3 year olds and the hamstring muscle among 4–6 year olds. Distal injections were predominantly administered to high-functioning children, whereas proximal injections were typically administered to low-functioning children. Multilevel injections were mostly administered to midfunctioning children. GMFM-88 scores significantly increased post-injection for both high- and low-functioning groups. Younger age at injection and distal injection type were associated with larger improvements on the GMFM-88 at both short- and midterm follow-up. The target muscles for injection varied depending on gross motor functioning and age. Younger age at injection and distal injection type were significantly related with greater gain in gross motor function.

Highlights

  • Botulinum toxin type A (BoNT-A) injections are widely used to control lower limb spasticity in children with spastic cerebral palsy (CP) [1,2]

  • A retrospective cohort registry study found that BoNT-A injections for children with CP differed according to age and level on the Gross Motor Function Classification System (GMFCS) [4]

  • 919 injection occasions from 591 participants were analyzed in this study

Read more

Summary

Introduction

Botulinum toxin type A (BoNT-A) injections are widely used to control lower limb spasticity in children with spastic cerebral palsy (CP) [1,2]. According to a population-based study, spasticity of the gastrocnemius muscle, as measured using the Modified Ashworth Scale (MAS), increases in most children with CP up to the age of 5, followed by a decrease up to the age of 15 [3]. A retrospective cohort registry study found that BoNT-A injections for children with CP differed according to age and level on the Gross Motor Function Classification System (GMFCS) [4]. As for equinus of the foot, the increasing muscle stiffness and joint tightness leads to limitation of joint motion (LOM) as the child grows. Cast applications are known to be useful to improve the passive range of motion (ROM)

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call